Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Development and validation of an integrated testing strategy for simultaneous detection of ESR-1 and gBRCA mutations via liquid biopsy in HR+/HER2- metastatic breast cancer (mBC) patients, and the creation of a digital gene library to support an evidence-based diagnostic algorithm
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak piersi, który reaguje na hormony (ER+/PgR+).
- •Rak piersi, który nie jest HER2-dodatni.
- •Choroba jest w zaawansowanym stadium lub rozprzestrzeniła się (przerzuty). Obejmuje to osoby przed rozpoczęciem leczenia przerzutów oraz te, które nie zareagowały na poprzednie leczenie inhibitorami CDK4/6.
- •Pacjentka musi wyrazić świadomą zgodę na udział w badaniu na piśmie.
✗ Disqualifies
- •Pacjentka nie może podpisać świadomej zgody na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 24, 2026
- Sex
- Female only
Locations (1)
European Institute of oncology
Milan, Italy
Trial contact
Nicola Fusco, MD
francesca lombardi, biologist
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.